Pieris Pharmaceuticals, Inc.

As of May 15, 2025, Pieris Pharmaceuticals, Inc. is considered overvalued with a price-to-book ratio of 5.13 and a negative return on equity of -30.71%, reflecting significant financial concerns and a stark contrast to its peers, despite a year-to-date stock return of 87.83% overshadowed by a three-year decline of -84.93%.

As of May 30, 2025, the trend is mildly bullish due to daily moving averages, but caution is advised as weekly indicators show mild bearishness and mixed monthly signals.

As of March 2022, the management team of Pieris Pharmaceuticals, Inc. includes Mr. James Geraghty (Independent Chairman), Mr. Stephen Yoder (President and CEO), and several Independent Directors: Dr. Ann Barbier, Dr. Peter Kiener, Mr. Christopher Kiritsy, Mr. Michael Richman, and Dr. Maya Said.

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company with a market cap of USD 238.34 million, focused on developing innovative therapies. As of March 2025, it reported a net profit loss of USD 8 million and has no dividend yield.

As of Jun 18, Pieris Pharmaceuticals, Inc. has a market capitalization of 238.34 million and reported net sales of 0.00 million with a net profit of -17.21 million over the latest four quarters. Shareholder's funds are 62.61 million, and total assets amount to 88.23 million.